Calquence (acalabrutinib) blocks the action of certain enzymes in the body, which can interfere with the growth and spread of cancer cells.
Calquence is used to treat mantle cell lymphoma (a type of non-Hodgkin lymphoma) in adults. This medicine is given after other treatments have failed.
Calquence was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, patients responded to this medicine. However, further studies are needed.
Calquence is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults.
